CRDFCardiff Oncology, Inc.

$133M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$136,000+163.1% YoY

Gross Profit

$136,000100.0% margin

Operating Income

-$4M-3208.1% margin

Net Income

-$4M-3306.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+216.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$39M

Total Liabilities

$6M

Stockholders' Equity

$34M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136,000	$51,687	+163.1%
Gross Profit	$136,000	-$3M	+104.9%
Operating Income	-$4M	-$4M	-3.7%
Net Income	-$4M	-$4M	-8.6%

CRDF Q3 2020 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena